GlaxoSmithKline (GS71) Stock Forecast & Price Target

6 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GS71 Analyst Ratings

Hold

3 Buy

8 Hold

3 Sell

Based on 14 analysts giving stock ratings to

GlaxoSmithKline

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GS71 Stock 12 Month Forecast

Average Price Target

€25.05

▲(15.79% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is €25.05 with a high forecast of €35.85 and a low forecast of €20.25. The average price target represents a 15.79% change from the last price of €21.63.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"€17","36":"€36","21.75":"€21.8","26.5":"€26.5","31.25":"€31.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.8536752,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€35.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.046261476923082,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€25.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.249584,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€20.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,21.75,26.5,31.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.09,22.225667323076923,23.361334646153846,24.49700196923077,25.632669292307693,26.768336615384616,27.904003938461535,29.03967126153846,30.175338584615382,31.311005907692305,32.44667323076923,33.58234055384615,34.718007876923075,{"y":35.8536752,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.09,21.39432780591716,21.69865561183432,22.00298341775148,22.30731122366864,22.6116390295858,22.91596683550296,23.22029464142012,23.52462244733728,23.82895025325444,24.1332780591716,24.437605865088763,24.74193367100592,{"y":25.046261476923082,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.09,21.025352615384616,20.960705230769232,20.896057846153845,20.83141046153846,20.766763076923077,20.702115692307693,20.637468307692306,20.57282092307692,20.508173538461538,20.443526153846154,20.378878769230766,20.314231384615383,{"y":20.249584,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.67,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.621,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.009,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.496,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.665,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.479,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":23.723,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 21</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.936,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.056,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.324,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.374,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 19</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.89,"date":1788220800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 19</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.09,"date":1790812800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€35.85

Average Price Target€25.05

Lowest Price Target€20.25

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Zain Ebrahim

J.P. Morgan

€20.25

Sell

-6.38%

Downside

Reiterated

10/21/26

GlaxoSmithKline (GSK) Receives a Sell from J.P. Morgan

James Gordon CFA

Barclays

€21.44

Sell

-0.88%

Downside

Reiterated

10/20/26

Barclays Sticks to Its Sell Rating for GlaxoSmithKline (GSK)

Trung Huynh

RBC Capital

€23.53

Hold

8.76%

Upside

Reiterated

10/19/26

RBC Capital Sticks to Its Hold Rating for GlaxoSmithKline (GSK)

Michael Leuchten

Jefferies

€29.78

Buy

37.67%

Upside

Reiterated

10/19/26

Jefferies Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)

Matthew Weston

UBS

€23.11

Hold

6.83%

Upside

Reiterated

10/15/26

UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)

Kerry Holford

Berenberg Bank

€26.21

Buy

21.15%

Upside

Reiterated

10/14/26

GlaxoSmithKline (GSK) Receives a Buy from Berenberg Bank

Rajan Sharma

Goldman Sachs

€22.63→€22.16

Hold

2.43%

Upside

Reiterated

10/05/26

Goldman Sachs Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Emmanuel Papadakis

Deutsche Bank

€23.82

Hold

10.14%

Upside

Reiterated

09/29/26

Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Graham Parry

Citi

€25.01

Hold

15.65%

Upside

Reiterated

09/15/26

GlaxoSmithKline (GSK) Receives a Hold from Citi

Rajesh Kumar

HSBC

€22.16→€23.82

Hold

10.14%

Upside

Reiterated

09/10/26

GSK price target raised to 2,000 GBp from 1,860 GBp at HSBCGSK price target raised to 2,000 GBp from 1,860 GBp at HSBC

Sachin Jain

Bank of America Securities

€27.99

Hold

29.41%

Upside

Reiterated

09/04/26

GSK: Pipeline Optionality Recognized but Near-Term Data Gaps Keep Rating at Hold and Price Target Unchanged at 2,350 GBp

Sarita Kapila

Morgan Stanley

€20.85→€22.63

Sell

4.63%

Upside

Reiterated

08/25/26

Morgan Stanley Keeps Their Sell Rating on GlaxoSmithKline (GSK)

Justin Smith

Bernstein

€33.65→€35.85

Buy

65.76%

Upside

Reiterated

08/03/26

Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

07/29/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

07/09/26

Guggenheim Remains a Hold on GlaxoSmithKline (GSK)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Zain Ebrahim

J.P. Morgan

€20.25

Sell

-6.38%

Downside

Reiterated

10/21/26

GlaxoSmithKline (GSK) Receives a Sell from J.P. Morgan

James Gordon CFA

Barclays

€21.44

Sell

-0.88%

Downside

Reiterated

10/20/26

Barclays Sticks to Its Sell Rating for GlaxoSmithKline (GSK)

Trung Huynh

RBC Capital

€23.53

Hold

8.76%

Upside

Reiterated

10/19/26

RBC Capital Sticks to Its Hold Rating for GlaxoSmithKline (GSK)

Michael Leuchten

Jefferies

€29.78

Buy

37.67%

Upside

Reiterated

10/19/26

Jefferies Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)

Matthew Weston

UBS

€23.11

Hold

6.83%

Upside

Reiterated

10/15/26

UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)

Kerry Holford

Berenberg Bank

€26.21

Buy

21.15%

Upside

Reiterated

10/14/26

GlaxoSmithKline (GSK) Receives a Buy from Berenberg Bank

Rajan Sharma

Goldman Sachs

€22.63→€22.16

Hold

2.43%

Upside

Reiterated

10/05/26

Goldman Sachs Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Emmanuel Papadakis

Deutsche Bank

€23.82

Hold

10.14%

Upside

Reiterated

09/29/26

Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Graham Parry

Citi

€25.01

Hold

15.65%

Upside

Reiterated

09/15/26

GlaxoSmithKline (GSK) Receives a Hold from Citi

Rajesh Kumar

HSBC

€22.16→€23.82

Hold

10.14%

Upside

Reiterated

09/10/26

GSK price target raised to 2,000 GBp from 1,860 GBp at HSBCGSK price target raised to 2,000 GBp from 1,860 GBp at HSBC

Sachin Jain

Bank of America Securities

€27.99

Hold

29.41%

Upside

Reiterated

09/04/26

GSK: Pipeline Optionality Recognized but Near-Term Data Gaps Keep Rating at Hold and Price Target Unchanged at 2,350 GBp

Sarita Kapila

Morgan Stanley

€20.85→€22.63

Sell

4.63%

Upside

Reiterated

08/25/26

Morgan Stanley Keeps Their Sell Rating on GlaxoSmithKline (GSK)

Justin Smith

Bernstein

€33.65→€35.85

Buy

65.76%

Upside

Reiterated

08/03/26

Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

07/29/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

07/09/26

Guggenheim Remains a Hold on GlaxoSmithKline (GSK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

SIBNSI-Bone

IMUXImmunic

MDWDMediwound

HROWHarrow Health

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline

3 Months

Kerry HolfordBerenberg Bank

Success Rate

19/34 ratings generated profit

Average Return

+0.95%

Copying Kerry Holford's trades and holding each position for 3 Months would result in 55.88% of your transactions generating a profit, with an average return of +0.95% per trade.

1 Year

Michael LeuchtenJefferies

Success Rate

21/33 ratings generated profit

Average Return

+4.29%

Copying Michael Leuchten's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +4.29% per trade.

2 Years

Justin SmithBernstein

Success Rate

13/22 ratings generated profit

Average Return

+9.13%

Copying Justin Smith's trades and holding each position for 2 Years would result in 59.09% of your transactions generating a profit, with an average return of +9.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GS71 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GS71 has received 7 Buy Ratings, 19 Hold Ratings, and 18 Sell Ratings. GS71 average Analyst price target in the past 3 months is 25.05.

Each month's total comprises the sum of three months' worth of ratings.

GS71 Financial Forecast

GS71 Earnings Forecast

Next quarter’s earnings estimate for GS71 is €0.60 with a range of €0.52 to €0.63. The previous quarter’s EPS was €0.60. GS71 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GS71 has Performed in-line its overall industry.

GS71 Sales Forecast

Next quarter’s sales forecast for GS71 is €10.56B with a range of €10.38B to €10.87B. The previous quarter’s sales results were €10.02B. GS71 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GS71 has Performed in-line its overall industry.

GS71 Stock Forecast FAQ

What is DE:GS71’s average 12-month price target, according to analysts?

Based on analyst ratings, GlaxoSmithKline’s 12-month average price target is 25.05.

What is DE:GS71’s upside potential, based on the analysts’ average price target?

GlaxoSmithKline has 15.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GlaxoSmithKline a Buy, Sell or Hold?

GlaxoSmithKline has a consensus rating of Hold, which is based on 3 buy ratings, 8 hold ratings and 3 sell ratings.

What is GlaxoSmithKline’s share price target?

The average share price target for GlaxoSmithKline is 25.05. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €35.85 ,and the lowest forecast is €20.25. The average share price target represents 15.79% Increase from the current price of €21.63.

What do analysts say about GlaxoSmithKline?

GlaxoSmithKline’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of GlaxoSmithKline?

To buy shares of DE:GS71, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

GlaxoSmithKline (GS71) Stock Forecast & Price Target

GS71 Analyst Ratings

GS71 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering GlaxoSmithKline

GS71 Analyst Recommendation Trends

GS71 Financial Forecast

GS71 Earnings Forecast

GS71 Sales Forecast

GS71 Stock Forecast FAQ

Detailed List of Analyst Forecasts